Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone

NCT ID: NCT07257198

Last Updated: 2025-12-08

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 2570 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-03-01
• Study Completion Date: 2031-01-01

Brief Summary

In patients with a myocardial infarction (MI) treated medically alone, the objective of the PANTHEON trial is to evaluate if ticagrelor monotherapy reduces bleeding events, without an increase in patient-oriented ischemic events, compared with standard dual antiplatelet therapy (DAPT) with aspirin and ticagrelor for 12 months.

Detailed Description

Coronary artery disease is associated with more than 9 million deaths per year worldwide. Following hospital discharge for an MI, both bleeding and recurrent ischemic events are associated with a high risk of subsequent mortality. However, the optimal antiplatelet strategy balancing bleeding and ischemic risks in the vulnerable population of patients with a medically managed MI patients (without revascularization) remains unknown, leading to substantial variability in clinical practice. This group represents 35-45% of patients wit hMI in Canada and the United States.

Primary Objectives To evaluate whether ticagrelor monotherapy is superior to dual antiplatelet therapy (DAPT) in reducing the risk of type 2, 3, or 5 bleeding events according to the BARC classification at 12 months.

To evaluate whether ticagrelor monotherapy is non-inferior to dual antiplatelet therapy (DAPT) for the composite endpoint of all-cause mortality, myocardial infarction, stroke, or coronary revascularization - a standardized, patient-centered ischemic clinical endpoint as defined by the Academic Research Consortium - at 12 months.

Secondary Objectives To evaluate differences between ticagrelor monotherapy and DAPT regarding the following endpoints at 12 months: individual components of the two primary endpoints; BARC type 3 or 5 bleeding; TIMI minor or major bleeding and its individual components; cardiovascular mortality; any coronary revascularization; the composite of all-cause mortality, MI, or stroke; and NACE, a composite of all-cause mortality, MI, stroke, any coronary revascularization, or type 2, 3, or 5 BARC bleeding.

Conditions

NSTEMI - Non-ST Segment Elevation MI; STEMI (ST Elevation MI); Myocardial Infarction

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Ticagrelor monotherapy

Ticagrelor 90 mg orally twice daily + placebo orally once daily

Group Type: EXPERIMENTAL

Ticagrelor + placebo

Intervention Type: DRUG

Ticagrelor 90 mg twice daily + placebo once daily

DAPT with ticagrelor and aspirin

Ticagrelor 90 mg orally twice daily + aspirin 80 mg orally once daily

Group Type: ACTIVE_COMPARATOR

Ticagrelor + aspirin

Intervention Type: DRUG

Ticagrelor 90 mg twice daily + aspirin 80 mg once daily

Interventions

Ticagrelor + placebo

Ticagrelor 90 mg twice daily + placebo once daily

Intervention Type: DRUG

Ticagrelor + aspirin

Ticagrelor 90 mg twice daily + aspirin 80 mg once daily

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Age ≥18 years;
• Hospitalized for type 1 MI, according to the 4th Universal Definition of MI;
• Coronary angiogram performed;
• Planned for medical management alone, without revascularization;
• Willingness to participate and to attend study visits;
• Expected life expectancy ≥12 months.

Exclusion Criteria

• Patients hospitalized for type 2-5 MI, or unstable angina, according to the 4th Universal Definition of MI;
• Patients hospitalized for a STEMI with an acute thrombotic lesion of a major epicardial vessel;
• Elevations in cardiac biomarkers (troponins or CK-MB) that is believed by the investigator not to be of ischemic origin (e.g. myocardial injury, myocarditis, Takotsubo syndrome, etc.);
• Confirmed or suspected spontaneous coronary artery dissection;
• Concomitant indication for chronic oral anticoagulant;
• Concomitant non-coronary indication for dual antiplatelet therapy;
• Use of any non-trial antiplatelet drug that needs to be continued based on the judgement of the treating physician;
• Previous hospitalization for MI, PCI, or CABG within 12 months;
• Known hypersensitivity, intolerance, or contra-indication to ASA or ticagrelor;
• Unsuitability for either randomization treatment, based on the judgement of the treating physician

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Montreal Heart Institute

OTHER

Sponsor Role: lead

Responsible Party

Guillaume Marquis-Gravel

Associate professor of clinic

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Montreal Heart Institute

Montreal, Quebec, Canada

Countries

Canada

Central Contacts

Guillaume Marquis-Gravel, MD

Role: CONTACT

guillaume.marquis.gravel@umontreal.ca

1-514-376-3330 ext. 2777

Roseline Therrien

Role: CONTACT

roseline.therrien@seriant.org

1-514-461-1300 ext. 2007

Facility Contacts

Guillaume Marquis-Gravel, MD

Role: primary

guillaume.marquis.gravel@umontreal.ca

1-514-376-3330 ext. 2777

Samara Bloom, Msc

Role: backup

samara.bloom@icm-mhi.org

1-514-376-3330 ext. 2698

Other Identifiers

202409PJT-525999-RC1-CFCK-1990

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

MP-33-2026-3610

Identifier Type: -

Identifier Source: org_study_id